吉利德科学将向私人控股的Ouro公司投资者支付约15亿美元现金作为预付款。此外,若达成特定临床试验里程碑,吉利德科学还将额外支付至少5亿美元资金。该交易结构凸显了生物医药行业对创新疗法的高估值趋势,资金支付与研发进展深度绑定的模式也成为当前并购交易的新特征。
吉利德科学将向私人控股的Ouro公司投资者支付约15亿美元现金作为预付款。此外,若达成特定临床试验里程碑,吉利德科学还将额外支付至少5亿美元资金。该交易结构凸显了生物医药行业对创新疗法的高估值趋势,资金支付与研发进展深度绑定的模式也成为当前并购交易的新特征。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.